ArticlemBio2020
Novel Antimicrobials from Uncultured Bacteria Acting against Mycobacterium tuberculosis.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Microbial Natural Products Targeting theMicroorganisms · 2026Review
- Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential.npj antimicrobials and resistance · 2026Review
- Review
- Mining Microbial Dark Matter: Advanced Cultivation Techniques for Bioactive Compound Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A chlorinated diketopiperazine antibiotic targetsAntimicrobial agents and chemotherapy · 2025Article
- Lasso peptides: A focus on therapeutic index.World journal of microbiology & biotechnology · 2025Review
- Total Synthesis and Structural Reassignment of the Antitubercular Natural Product Evybactin.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Harnessing iChip technology for novel antibiotic discovery from peat soil microbiomes to combat antimicrobial resistance.Frontiers in microbiology · 2025Article
- Assessing Normandy Soil Microbial Diversity for Antibacterial Activities Using Traditional Culture and iChip Methods.Microorganisms · 2024Article
- Phenotypic heterogeneity in bacteria: the rise of antibiotic persistence, clinical implications, and therapeutic opportunities.Archives of microbiology · 2024Review
- Sophisticated natural products as antibiotics.Nature · 2024Review
- Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024Review
- Interplay of emerging and established technologies drives innovation in natural product antibiotic discovery.Current opinion in microbiology · 2023Review
- A new antibiotic from an uncultured bacterium binds to an immutable target.bioRxiv : the preprint server for biology · 2023Article
- Modern Trends in Natural Antibiotic Discovery.Life (Basel, Switzerland) · 2023Review
- Computational identification of a systemic antibiotic for gram-negative bacteria.Nature microbiology · 2022Article
- Next-generation sequencing: insights to advance clinical investigations of the microbiome.The Journal of clinical investigation · 2022Review
- Impact of novel microbial secondary metabolites on the pharma industry.Applied microbiology and biotechnology · 2022Review
- A selective antibiotic for Lyme disease.Cell · 2021Article
- Ribosome hibernation: a new molecular framework for targeting nonreplicating persisters of mycobacteria.Microbiology (Reading, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.